Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus
Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus
复制标题
DOI：
10.1111/j.1600-0781.2008.00373.x
复制
发表时间：
2008-10-01
影响因子：
2.6
通讯作者：
Murphy, Gillian M.
中科院分区：
文献类型：
--
作者：
Cusack, Caitriona;Danby, Claire;Murphy, Gillian M.
背景：阳光照射皮肤，独立于饮食来源，可以为健康个体提供足够的维生素D。最近的一项研究皮肤红斑狼疮患者的结论是，超过70%的人限制他们的sunexposed.Methods：我们招募了52例活检证实皮肤红斑狼疮，以确定他们是否缺乏25-羟基维生素D [25（OH）D]。我们在夏季测量了他们的血清25（OH）D水平，研究了几个变量对25（OH）D水平的影响，并评估了维生素D补充剂的作用。结果：总体平均25（OH）D水平为63.03（+/- 23.3）nmol/l。在2名（3.8%）患者中记录到显著低值（< 25 nmol/l），在34名（65.4%）患者中发现浓度低于75 nmol/l。25（OH）D水平在避免阳光和日常防晒霜使用者中显着较低，而在服用胆钙化醇（维生素D3）补充剂的人中发现显着较高的值。低价值记录在那些肾脏疾病，尽管补充维生素D3在某些cases.Conclusions：我们认为，皮肤狼疮患者有次优的25（OH）D水平，这是显着增加了至少400 IU/天的胆钙化醇。我们建议与肾脏病专家顾问合作，对肾脏病患者亚组补充活性维生素D类似物。
Background: Sun exposure of the skin, independent of dietary sources, may provide sufficient vitamin D in healthy individuals. A recent study of patients with cutaneous lupus erythematosus concluded that over 70% of them restrict their sun exposure.Methods: We recruited 52 patients with biopsy-proven cutaneous lupus erythematosus to establish whether they are deficient in 25-hydroxyvitamin D [25(OH)D]. We measured their serum 25(OH)D levels during summer months, investigated the effects of several variables on 25(OH)D levels and assessed the role of vitamin D supplementation.Results: An overall mean 25(OH)D level of 63.03 (+/- 23.3) nmol/l was obtained. Significantly low values (< 25 nmol/l) were recorded in two (3.8%) patients and concentrations below 75 nmol/l were found in 34 (65.4%) patients. 25(OH)D levels were significantly lower among sun avoiders and daily sunscreen users, while significantly higher values were found among those who took cholecalciferol (vitamin D3) supplements. Low values were recorded among those with renal disease despite supplementation with vitamin D3 in some cases.Conclusions: We suggest that patients with cutaneous lupus erythematous have suboptimal 25(OH)D levels, which are significantly raised by the addition of at least 400 IU/day of cholecalciferol. We recommend supplementation with an active vitamin D analogue in collaboration with a consultant nephrologist, for the subgroup of patients with renal disease.